Back to search results

Long-term Follow-up for CAR-T Cell Therapy

This study is observing people who have already received CAR-T cells (a type of cell therapy where your own immune cells are specially trained to fight cancer) in a previous clinical trial at Froedtert Hospital & the Medical College of Wisconsin. The goal is to understand the long-term safety and effectiveness of CAR-T cell treatments for conditions like Chronic Lymphocytic Leukemia and different types of Lymphoma. Researchers will be looking for how often new cancers develop at 5, 10, and 15 years after treatment. You can join if you are between 18 and 80 years old and have participated in a CAR-T study at Froedtert Hospital & the Medical College of Wisconsin. The study is currently unclear on its recruitment status.

Study design
This is an observational study following 500 participants who previously received CAR-T cell therapy.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 15 years after their CAR-T cell treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03375619

Long-term Follow-up Study of Patients Receiving CAR-T Cells

Recruiting
Not specifiedAges 18–80Observational
Medical College of Wisconsin
~500 participants
Updated 2025-11-10 on ClinicalTrials.gov
What's tested:Long-Term Follow-Up of Participants who Received CAR-T cells

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline in the incidence of a new malignancy at 5 years.
Measured over Baseline to five years.
+2 more outcomes measured

Conditions

Chronic Lymphocytic Leukemia
Lymphomas Non-Hodgkin's B-Cell
Lymphoma, Small Lymphocytic
Mantle Cell Lymphoma
Central Nervous System Lymphoma
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Burkitt Lymphoma
Multiple Myeloma

Explore related trials

B-Cell Non-Hodgkin LymphomaBurkitt LymphomaCentral Nervous System LymphomaChronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular LymphomaMantle Cell LymphomaMultiple MyelomaSmall Lymphocytic Lymphoma

Where it's being run

1 sites across 1 states
Wisconsin1

Study leadership

  • Nirav Shah · PRINCIPAL_INVESTIGATOR · Medical College of Wisconsin

Who to contact

Medical College of Wisconsin Clinical Cancer Center
[email protected]
414-805-8900
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All participants who enrolled in a CAR-T study at Froedtert Hospital \& the Medical College of Wisconsin.

What this trial measures

  • Change from baseline in the incidence of a new malignancy at 5 years.Baseline to five years.

    The number of subjects with new malignancy.

  • Change from baseline in the incidence of a new malignancy at 10 years.Baseline to 10 years.

    The number of subjects with new malignancy.

  • Change from baseline in the incidence of a new malignancy at 15 years.Baseline to 15 years.

    The number of subjects with new malignancy.